
ALLO Stock Forecast & Price Target
ALLO Analyst Ratings
Bulls say
Allogene Therapeutics Inc is demonstrating a positive outlook driven by its strategic pivot to standard FC lymphodepletion in the ALPHA3 trial, prioritizing patient safety and simplifying clinical protocols. The company has captured over 90% patient consent for minimal residual disease (MRD) screening, with positivity rates indicating a substantial patient pool for potential enrollment, ensuring robust ongoing research and development. Positive feedback from investigators regarding the regimen simplification further supports the potential for enhanced real-world adoption of Allogene's therapies, mitigating complexities and associated infection risks.
Bears say
Allogene Therapeutics Inc faces substantial risks associated with the approval processes for their clinical-stage products, with potential delays or failures in achieving regulatory approval likely to adversely affect the company's share price. Additionally, the inherent uncertainties of clinical trials raise concerns about the efficacy and safety of Allogene's assets, which may fail to meet necessary standards in current or future evaluations. Furthermore, the company faces significant regulatory and commercial risks that pose additional challenges to its operational and financial stability.
This aggregate rating is based on analysts' research of Allogene Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ALLO Analyst Forecast & Price Prediction
Start investing in ALLO
Order type
Buy in
Order amount
Est. shares
0 shares